BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
30.77
-0.16 (-0.52%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close30.93
Open30.78
Bid0.00 x 0
Ask0.00 x 0
Day's Range30.75 - 30.93
52 Week Range27.60 - 35.41
Volume185,596
Avg. Volume340,816
Market Cap105.461B
Beta1.21
PE Ratio (TTM)11.90
EPS (TTM)2.59
Earnings DateN/A
Forward Dividend & Yield0.86 (2.81%)
Ex-Dividend Date2018-05-25
1y Target Est35.33
Trade prices are not sourced from all markets
  • Bayer cuts full-year earnings guidance on strong euro
    Reuters Videos18 days ago

    Bayer cuts full-year earnings guidance on strong euro

    Bayer says the pressure from a stronger euro on overseas revenues would translate into a decline in earnings this year, as it prepares to close its $62.5 billion takeover of U.S. seeds maker Monsanto next quarter. Sonia Legg reports.

  • InvestorPlace5 days ago

    Warren Buffett’s Best Dividend Stocks

    Berkshire owns a collection of operating companies and plenty of financial assets ranging from bonds to synthetic securities and, of course, lots of cash. Form 13F is for any investment management company with more than $100 million in discretionary investments.

  • Why Bayer Aktiengesellschaft (BAYRY) Might Surprise This Earnings Season
    Zacks6 days ago

    Why Bayer Aktiengesellschaft (BAYRY) Might Surprise This Earnings Season

    Bayer Aktiengesellschaft (BAYRY) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

  • Reuters9 days ago

    Bayer CFO sees lower Monsanto synergies after divestments: Boersen-Zeitung

    Bayer's potential synergies from buying U.S. rival Monsanto will be lower than $1.5 billion because of anti-trust divestments, the German company's Chief Financial Officer told Germany's Boersen-Zeitung. The $1.5 billion savings targeted within three years are a "pro forma" synergy goal, which excluded the impact of divestments, Johannes Dietsch told the newspaper. "The basis for revenue synergies is now lower.

  • Bayer CFO sees lower Monsanto synergies after divestments: Boersen-Zeitung
    Reuters9 days ago

    Bayer CFO sees lower Monsanto synergies after divestments: Boersen-Zeitung

    Bayer's potential synergies from buying U.S. rival Monsanto will be lower than $1.5 billion because of anti-trust divestments, the German company's Chief Financial Officer told Germany's Boersen-Zeitung. The $1.5 billion savings targeted within three years are a "pro forma" synergy goal, which excluded the impact of divestments, Johannes Dietsch told the newspaper. "The basis for revenue synergies is now lower.

  • Does Bayer Aktiengesellschaft’s (FRA:BAYN) Debt Level Pose A Problem?
    Simply Wall St.11 days ago

    Does Bayer Aktiengesellschaft’s (FRA:BAYN) Debt Level Pose A Problem?

    Investors pursuing a solid, dependable stock investment can often be led to Bayer Aktiengesellschaft (DB:BAYN), a large-cap worth €87.17B. Risk-averse investors who are attracted to diversified streams of revenue andRead More...

  • Associated Press13 days ago

    Monsanto CEO and others to leave after Bayer takeover

    ST. LOUIS (AP) — Monsanto Chairman and CEO Hugh Grant will leave the company after it's acquired by Germany's Bayer AG.

  • Monsanto CEO Grant to make way for Bayer's Condon post-takeover
    Reuters14 days ago

    Monsanto CEO Grant to make way for Bayer's Condon post-takeover

    Grant became CEO in 2003 and will leave following the close of the deal, along with other senior executives including Chief Financial Officer Pierre Courduroux and Chief Technology Officer Robert Fraley, Monsanto said on Monday. German conglomerate Bayer is preparing to close its $62.5 billion takeover of Monsanto this quarter, giving it control of more than 25 percent of the world's seed and pesticides market.

  • Reuters14 days ago

    Monsanto CEO Grant to make way for Bayer's Condon post-takeover

    Monsanto Co's Chief Executive Officer Hugh Grant will step down when Bayer AG completes the takeover of the U.S. seeds company, making way for Bayer executive Liam Condon to lead the combined crop sciences business. Grant became CEO in 2003 and will leave following the close of the deal, along with other senior executives including Chief Financial Officer Pierre Courduroux and Chief Technology Officer Robert Fraley, Monsanto said on Monday.

  • The Wall Street Journal14 days ago

    [$$] Monsanto CEO to Leave After Sale to Bayer

    Mr. Grant has worked at Monsanto for 35 years and has served as chairman and CEO since 2003. and a number of other top executives, such as the company’s general counsel and chief technology officer, are also leaving after the deal is completed, Monsanto said Monday.

  • Face of GMOs at Monsanto to Step Down as Bayer Takeover Closes
    Bloomberg14 days ago

    Face of GMOs at Monsanto to Step Down as Bayer Takeover Closes

    It’s the end of an era at Monsanto Co. after executives including the seed giant’s scientific leader Robb Fraley announced plans to depart after the company’s takeover by Germany’s Bayer AG. Fraley will depart “shortly after closing” on the Bayer deal, following a transition period, Monsanto said Monday in a statement. The $66 billion takeover by Germany’s Bayer is expected to close during the current quarter.

  • Reuters14 days ago

    Monsanto says CEO Hugh Grant will step down after Bayer deal closes

    Monsanto Co said on Monday Chief Executive Officer Hugh Grant will step down after the seeds company completes a deal to be acquired by Bayer AG. German conglomerate Bayer is preparing to close its $62.5 ...

  • MarketWatch14 days ago

    Monsanto CEO Hugh Grant says he will step down once the Bayer deal closes

    Monsanto Co. Chief Executive Hugh Grant said Monday he will step down and leave the company once the company's takeover by Bayer AG has closed. Grant will remain as CEO and chairman until then, he said ...

  • Reuters17 days ago

    Bayer sells further Covestro stake for 2.2 billion euros

    Pharmaceutical group Bayer has sold a further stake in plastics company Covestro for 2.2 billion euros ($2.64 billion), placing a holding of 14.2 percent via an accelerated bookbuilding process. Covestro was spun off from Bayer in 2015, and Bayer said this latest sale marks the start of the full separation from its former unit. Bayer, which is buying seed maker Monsanto, raised 1.8 billion euros ($2.15 billion) in January by selling a 10.4 percent stake in Covestro.

  • Bayer Boosts Finances With $2.6 Billion Covestro Stake Sale
    Bloomberg17 days ago

    Bayer Boosts Finances With $2.6 Billion Covestro Stake Sale

    Bayer AG sold its remaining stake in Covestro AG, raising 2.2 billion euros ($2.6 billion) as the German drugmaker closes in on the planned $66 billion purchase of genetically modified seeds supplier Monsanto Co. Bayer sold 28.8 million, or 14 percent, of Covestro’s shares for 75.50 euros each, the company said in a statement on Friday. The transaction began after markets closed on Thursday and was managed by Bank of America Corp. and JPMorgan Chase and Co.

  • Bayer (BAYRY) Misses Earnings and Revenue Estimates in Q1
    Zacks18 days ago

    Bayer (BAYRY) Misses Earnings and Revenue Estimates in Q1

    Bayer (BAYRY) misses first-quarter 2018 earnings and sales estimates.

  • White House Asked to Fight Opioids by Overriding Drug Patents
    Bloomberg18 days ago

    White House Asked to Fight Opioids by Overriding Drug Patents

    The city of Baltimore and a consumer group are asking the Trump administration to fight the opioid epidemic with a novel weapon: overriding U.S. patents on the overdose antidote naloxone. By overriding patents for easy-to-use naloxone treatments including Kaleo Inc.’s injectable Evzio and closely held Adapt Pharma Inc.’s Narcan nasal spray, the government could reduce the cost and increase availability of the antidote, Baltimore’s health department and the advocacy group Public Citizen said in a letter to the White House on Thursday.

  • How Can U.S. Fight the Opioid Crisis? Try Antidote Patents
    Bloomberg18 days ago

    How Can U.S. Fight the Opioid Crisis? Try Antidote Patents

    The Trump administration should fight the opioid epidemic with a novel weapon, say the city of Baltimore and a consumer advocacy group: overriding patents on the widely-used overdose antidote naloxone. By overriding patents for naloxone treatments including Kaleo Inc.’s injectable Evzio and Adapt Pharma Inc.’s Narcan nasal spray, the government could lower the cost and increase availability of the antidote, Baltimore’s health department and Public Citizen said in a letter to the White House on Thursday.

  • Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View
    Zacks18 days ago

    Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View

    Regeneron's (REGN) first-quarter results were mixed as earnings beat expectations while sales missed the same. Nevertheless, Eylea sales were impressive.

  • Investors Unruffled After Bayer Cuts 2018 Forecast: Street Wrap
    Bloomberg18 days ago

    Investors Unruffled After Bayer Cuts 2018 Forecast: Street Wrap

    A reduced profit forecast failed to make a dent in Bayer AG shares, with the company attributing the revision to currency swings and analysts applauding first-quarter earnings that beat estimates. The stock gained slightly, with confirmation that the drugmaker aims to close its takeover of Monsanto Co. by the end of this quarter providing further reassurance. The cut to guidance was small and has already been incorporated into estimates, most analysts said.

  • Reuters18 days ago

    Bayer cuts full-year earnings guidance on strong euro

    Bayer said the pressure from a stronger euro on overseas revenues would translate into a decline in earnings this year, as it prepares to close its $62.5 billion takeover of U.S. seeds maker Monsanto this quarter. Sales at the German drug and crop chemicals maker will likely decline by a low single-digit percentage to less than 35 billion euros ($42 billion) this year, Bayer said, having previously predicted sales of about 35 billion euros. The average value of the euro against the dollar during the first quarter was about 14 percent above a year earlier, which has hurt euro zone exporters.

  • Reuters18 days ago

    Bayer cuts full-year earnings guidance on strong euro

    Bayer said the pressure from a stronger euro on overseas revenues would translate into a decline in earnings this year, as it prepares to close its $62.5 billion takeover of U.S. seeds maker Monsanto this quarter. Sales at the German drug and crop chemicals maker will likely decline by a low single-digit percentage to less than 35 billion euros ($42 billion) this year, Bayer said, having previously predicted sales of about 35 billion euros. The average value of the euro against the dollar during the first quarter was about 14 percent above a year earlier, which has hurt euro zone exporters.

  • The Wall Street Journal18 days ago

    [$$] Forex Weighs Down Bayer's 1Q

    Bayer lowered its 2018 guidance after first-quarter net profit fell 6.2%, weighed down by adverse currency swings.

  • Bloomberg18 days ago

    Bayer Trims Annual Forecasts Amid Monsanto Deadline Push

    Bayer AG cut its forecast for the year because the euro’s strength is curbing sales as it pushes to close its $66 billion purchase of Monsanto Co. Bayer had previously predicted that sales and profit would show little change without Monsanto and without adjusting for exchange rates. Bayer Chief Executive Werner Baumann repeated that he aims to close the Monsanto acquisition, announced in mid-2016, by the end of this quarter.